Barclays’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-537,061
| Closed | -$10.8M | – | 5493 |
|
|
2026
Q1 | $10.8M | Sell |
537,061
-163,512
| -23% | -$2.64M | ﹤0.01% | 1412 |
|
|
2025
Q4 | $11.3M | Buy |
700,573
+122,669
| +21% | +$1.62M | ﹤0.01% | 1600 |
|
|
2025
Q3 | $7.04M | Buy |
577,904
+408,981
| +242% | +$5.65M | ﹤0.01% | 1950 |
|
|
2025
Q2 | $1.91M | Buy |
168,923
+113,696
| +206% | +$1.39M | ﹤0.01% | 2884 |
|
|
2025
Q1 | $637K | Sell |
55,227
-12,835
| -19% | -$131K | ﹤0.01% | 3375 |
|
|
2024
Q4 | $576K | Buy |
68,062
+840
| +1% | +$8.7K | ﹤0.01% | 3736 |
|
|
2024
Q3 | $778K | Buy |
67,222
+54,257
| +418% | +$682K | ﹤0.01% | 3518 |
|
|
2024
Q2 | $153K | Sell |
12,965
-8,990
| -41% | -$105K | ﹤0.01% | 3712 |
|
|
2024
Q1 | $260K | Sell |
21,955
-20,576
| -48% | -$274K | ﹤0.01% | 3975 |
|
|
2023
Q4 | $521K | Buy |
42,531
+38,316
| +909% | +$349K | ﹤0.01% | 3844 |
|
|
2023
Q3 | $40.6K | Sell |
4,215
-691
| -14% | -$7.06K | ﹤0.01% | 3950 |
|
|
2023
Q2 | $44.2K | Sell |
4,906
-7,507
| -60% | -$69.2K | ﹤0.01% | 3895 |
|
|
2023
Q1 | $97.6K | Buy |
12,413
+5,841
| +89% | +$43.6K | ﹤0.01% | 4197 |
|
|
2022
Q4 | $44.4K | Buy |
6,572
+3,923
| +148% | +$21K | ﹤0.01% | 4591 |
|
|
2022
Q3 | $38K | Buy |
2,649
+679
| +34% | +$9.49K | ﹤0.01% | 3861 |
|
|
2022
Q2 | $19K | Sell |
1,970
-1,668
| -46% | -$18.4K | ﹤0.01% | 4424 |
|
|
2022
Q1 | $54K | Sell |
3,638
-25,348
| -87% | -$364K | ﹤0.01% | 4090 |
|
|
2021
Q4 | $383K | Buy |
28,986
+18,582
| +179% | +$296K | ﹤0.01% | 3313 |
|
|
2021
Q3 | $181K | Buy |
10,404
+5,335
| +105% | +$108K | ﹤0.01% | 3669 |
|
|
2021
Q2 | $122K | Sell |
5,069
-28,214
| -85% | -$738K | ﹤0.01% | 3768 |
|
|
2021
Q1 | $854K | Buy |
33,283
+19,603
| +143% | +$515K | ﹤0.01% | 2868 |
|
|
2020
Q4 | $260K | Sell |
13,680
-978
| -7% | -$16.8K | ﹤0.01% | 3616 |
|
|
2020
Q3 | $185K | Buy |
14,658
+657
| +5% | +$8.21K | ﹤0.01% | 3898 |
|
|
2020
Q2 | $169K | Buy |
14,001
+3,322
| +31% | +$35.3K | ﹤0.01% | 4187 |
|
|
2020
Q1 | $82K | Sell |
10,679
-14,217
| -57% | -$192K | ﹤0.01% | 4924 |
|
|
2019
Q4 | $444K | Buy |
24,896
+6,862
| +38% | +$89.6K | ﹤0.01% | 4398 |
|
|
2019
Q3 | $209K | Sell |
18,034
-4,973
| -22% | -$80.3K | ﹤0.01% | 4933 |
|
|
2019
Q2 | $510K | Sell |
23,007
-9,482
| -29% | -$222K | ﹤0.01% | 4306 |
|
|
2019
Q1 | $930K | Sell |
32,489
-30,289
| -48% | -$657K | ﹤0.01% | 3478 |
|
|
2018
Q4 | $1.24M | Buy |
62,778
+62,707
| +88,320% | +$1.26M | ﹤0.01% | 2898 |
|
|
2018
Q3 | $2K | Buy |
+71
| New | +$960 | ﹤0.01% | 6945 |
|
|
2018
Q1 | – | Sell |
-1,349
| Closed | -$13K | – | 7193 |
|
|
2017
Q4 | $13K | Buy |
+1,349
| New | +$14K | ﹤0.01% | 6445 |
|
|
2016
Q3 | – | Sell |
-32
| Closed | – | – | 6703 |
|
|
2016
Q2 | $0 | Buy |
+32
| New | +$371 | ﹤0.01% | 6470 |
|
|
2015
Q4 | – | Sell |
-5
| Closed | – | – | 6272 |
|
|
2015
Q3 | $0 | Sell |
5
-12
| -71% | -$1.02K | ﹤0.01% | 6943 |
|
|
2015
Q2 | $2K | Buy |
+17
| New | +$1.69K | ﹤0.01% | 6805 |
|
Other funds holding KALV
Barclays's KALV Position: Q2 2026 in Review
Barclays sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 537,061 shares — an estimated $10.8M sold.
Barclays first reported a position in KALV in Q2 2015 and held it in 35 quarters. The position peaked at $11.3M in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Barclays reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Barclays sold 537,061 KalVista Pharmaceuticals shares in Q2 2026, an estimated $10.8M.
- Barclays first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 35 quarters.
- Barclays's KalVista Pharmaceuticals position peaked at $11.3M in Q4 2025.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.